Oral Surgery Oral Medicine Oral Pathology Oral Radiology最新文献

{"title":"Oral manifestations of peripheral T cell lymphoma, not otherwise specified: case series and review of the current literature","authors":"Eduardo Morato de Oliveira ,&nbsp;Cinthia Veronica Bardález Lopéz de Cáceres ,&nbsp;Carla Isabelly Fernandes-Rodrigues ,&nbsp;Paulo Victor Mendes Penafort ,&nbsp;Juan Manuel Arteaga Legarrea ,&nbsp;Nathalia Rodrigues Gomes ,&nbsp;Hélder Antônio Rebelo Pontes ,&nbsp;Pablo Agustin Vargas ,&nbsp;José Narciso Rosa Assunção Júnior ,&nbsp;Ciro Dantas Soares ,&nbsp;Felipe Paiva Fonseca","doi":"10.1016/j.oooo.2024.08.011","DOIUrl":"10.1016/j.oooo.2024.08.011","url":null,"abstract":"<div><h3>Objective</h3><div>The objective of this study was to describe a series of peripheral T-cell lymphoma, not otherwise specified (PTCL NOS) affecting the oral cavity and to review the available literature.</div></div><div><h3>Study Design</h3><div>Cases diagnosed as PTCL-NOS affecting the oral cavity were retrospectively retrieved from pathology files. Original hematoxylin and eosin-stained slides and immunohistochemical reactions were reviewed for microscopic confirmation. The presence of Epstein-Barr virus (EBV) was investigated by in situ hybridization. Clinical and follow-up data were retrieved from patients’ pathology and medical files.</div></div><div><h3>Results</h3><div>A total of 5 cases were obtained with a mean age of 51.8 years old, 3 male patients and 2 female patients. Three cases affected the palate and 2 cases affected the gingiva, whereas 1 case affected the maxillary bone. Tumors presented as destructive, infiltrative, and painful lesions causing swelling, ulceration, and tissue necrosis. All cases exhibited CD3 expression. GATA3 was expressed in 3 cases. Four patients were deceased of the disease during follow-up.</div></div><div><h3>Conclusions</h3><div>PTCL NOS affecting the oral cavity is rare and usually present as a very aggressive disease, associated with a poor prognosis and dismal outcome. (Oral Surg Oral Med Oral Pathol Oral Radiol YEAR;VOL:page range)</div></div>","PeriodicalId":49010,"journal":{"name":"Oral Surgery Oral Medicine Oral Pathology Oral Radiology","volume":"139 2","pages":"Pages e37-e45"},"PeriodicalIF":2.0,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142113857","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Adverse effects associated with the irresponsible use of phenol peeling: literature review","authors":"Nathaly de Oliveira Ciaramicolo DDS, MS ,&nbsp;Gabriela Barbosa Bisson DDS, MS ,&nbsp;Osny Ferreira Júnior DDS, MSc","doi":"10.1016/j.oooo.2024.08.018","DOIUrl":"10.1016/j.oooo.2024.08.018","url":null,"abstract":"<div><div>Carbolic acid or phenol is considered a chemical agent that produces intense facial rejuvenation when used correctly, however, solutions containing this substance are dangerous and their action must be controlled. The aim of this study was to collect information on the adverse effects of the use of phenolic compounds for facial esthetic purposes. Phenol promotes the denaturation and coagulation of epidermal keratin proteins, deep chemical peels carried out with phenol, when well indicated and properly conducted, produce incomparable results, however, the ignorant use of these solutions can produce ectropion, keloids, and unsightly scars on the face and neck, in addition, systemic absorption is related to hepatorenal and cardiac toxicity. Although the cardiotoxicity of phenol is well described in the literature, its carcinogenic potential is still unknown and further studies are needed. It is known that the substance induces unscheduled DNA synthesis, inducing genetic mutation. Successful results depend on a balance among art and technique and safety standards. Future research investigating the carcinogenic potential of phenol peels is desirable to ensure patient safety and adequate information for professionals. We believe that the indiscriminate use of phenol peels can cause serious problems for patients and their general health. (Oral Surg Oral Med Oral Pathol Oral Radiol YEAR;VOL:page range)</div></div>","PeriodicalId":49010,"journal":{"name":"Oral Surgery Oral Medicine Oral Pathology Oral Radiology","volume":"139 2","pages":"Pages 161-165"},"PeriodicalIF":2.0,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142267336","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of radiotherapy on peripheral T lymphocytes in hypopharyngeal squamous cell carcinoma","authors":"Hanqing Lin MD, PhD ,&nbsp;Yu Heng MS ,&nbsp;Xiaoke Zhu MS ,&nbsp;Tian Wang MS ,&nbsp;Lei Tao MD, PhD","doi":"10.1016/j.oooo.2024.10.080","DOIUrl":"10.1016/j.oooo.2024.10.080","url":null,"abstract":"<div><h3>Background</h3><div>To investigate the impact of radiotherapy (RT) on the distribution and function of peripheral CD8⁺ T lymphocytes in patients with hypopharyngeal squamous cell carcinoma (HPSCC).</div></div><div><h3>Methods</h3><div>A total of 105 HPSCC patients who underwent definitive RT were enrolled. Baseline levels of peripheral immune cells were obtained, and their alteration during RT was evaluated. Flow cytometry was used to analyze T-cell distribution, cytokine secretion, and CD8⁺ T lymphocyte proliferation capacity.</div></div><div><h3>Results</h3><div>Lymphocyte count significantly decreased following radiation and remained in a low level after 1 year of RT. CD3⁺ T lymphocyte counts decreased significantly, and the CD4⁺/CD8⁺ ratio increased in HPSCC patients following radiation. The secretion of IFN-γ from peripheral CD8+ T lymphocytes was significantly reduced after irradiation, while the secretion of TNF-α and perforin did not change significantly. Furthermore, the proliferation capacity of peripheral CD8⁺ T lymphocytes was decreased following RT.</div></div><div><h3>Conclusions</h3><div>RT significantly decreased the number of peripheral T lymphocytes and impaired the secretory function and proliferation ability of CD8⁺ T lymphocytes in HPSCC patients. These findings provide insight into the mechanisms underlying the therapeutic effects of RT on HPSCC and have implications for optimizing treatment strategies.</div></div>","PeriodicalId":49010,"journal":{"name":"Oral Surgery Oral Medicine Oral Pathology Oral Radiology","volume":"139 2","pages":"Pages 220-228"},"PeriodicalIF":2.0,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142630966","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Adenomatoid hyperplasia of minor salivary glands: a systematic review","authors":"Gabriel Lima Braz DDS ,&nbsp;Ana Carolina Uchoa Vasconcelos DDS, PhD ,&nbsp;Ana Paula Neutzling Gomes DDS, PhD ,&nbsp;Camila Barcellos Calderipe DDS ,&nbsp;Alini Cardoso Soares DDS","doi":"10.1016/j.oooo.2024.10.081","DOIUrl":"10.1016/j.oooo.2024.10.081","url":null,"abstract":"<div><h3>Objective</h3><div>To systematically review available data regarding adenomatoid hyperplasia of minor salivary glands (AHMSG).</div></div><div><h3>Study Design</h3><div>Electronic searches were performed in six databases and gray literature. The risk of bias was assessed using the Joanna Briggs Institute tool.</div></div><div><h3>Results</h3><div>Forty studies reporting 121 cases of AHMSG were included. There is a male predominance (<em>n</em> = 72/64.29%), with individuals in their fourth and fifth decade of life being the most affected. The palate was the main anatomical location (<em>n</em> = 90/74.39%), and most lesions presented as single, asymptomatic nodules. The mean size of AHMSGs was 1.48 ± 0.77 cm, and the mean evolution time was 16.84 ± 25.67 months. Immunohistochemical evaluation in three cases (2.48%) showed a low labeling index for Ki-67 (<em>n</em> = 2/66.67%) and proliferating cell nuclear antigen (<em>n</em> = 1/33.33%).</div></div><div><h3>Conclusions</h3><div>AHMSG is an uncommon benign lesion with no tendency to recur after initial surgical removal. The main histological features include an abundant proliferation of glandular acini, occasional ductal dilation, and sometimes the presence of inflammatory infiltrate. Pathologists and clinicians should be aware of AHMSG, as it can closely resemble both benign and malignant salivary gland lesions.</div></div>","PeriodicalId":49010,"journal":{"name":"Oral Surgery Oral Medicine Oral Pathology Oral Radiology","volume":"139 2","pages":"Pages 229-241"},"PeriodicalIF":2.0,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142689377","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"An ex vivo comparison of near-infrared Raman spectroscopy and cone beam computed tomography in the assessment of bone, dental hard tissues, and bone graft materials","authors":"Anusha Vaddi BDS, MDentSci ,&nbsp;Aditya Tadinada BDS, MDentSci ,&nbsp;Alix Deymier PhD","doi":"10.1016/j.oooo.2024.10.076","DOIUrl":"10.1016/j.oooo.2024.10.076","url":null,"abstract":"<div><h3>Objective</h3><div>To evaluate the potential of near-infrared Raman spectroscopy (RS) in distinguishing between various types of bone, dental hard tissues, and bone graft materials, and to determine the correlation between pixel intensity values (PIVs) in cone beam computed tomography (CBCT) and Raman values.</div></div><div><h3>Study Design</h3><div>A thinly sliced section of mandible was utilized to evaluate cancellous and cortical bone. Extracted human teeth were used to prepare the enamel and dentin samples. Bone graft materials were tested by compacting them into edentulous tooth sockets in a dry human mandible. CBCT and RS scans of the samples were performed. The following RS outcomes were evaluated: 960 cm^-1 phosphate peak location and width, carbonate:phosphate ratio, mineral:matrix ratio, and collagen coiling ratio. One-way ANOVA and primary component analysis (PCA) statistics were used to assess RS outcomes.</div></div><div><h3>Results</h3><div>The 960 cm^-1 phosphate peak location was able to effectively differentiate between various tissues and graft materials. PCA of the spectra successfully differentiated native bone from graft materials, underscoring the tissue characterization capability of RS. Varied correlations between RS outcomes and CBCT PIVs were observed.</div></div><div><h3>Conclusions</h3><div>Various parameters of RS can differentiate between cancellous bone, cortical bone, dental hard tissues, and bone graft materials. The varied correlations between Raman parameters and CBCT PIVs warrant further research to clarify the nature of these relationships.</div></div>","PeriodicalId":49010,"journal":{"name":"Oral Surgery Oral Medicine Oral Pathology Oral Radiology","volume":"139 2","pages":"Pages 248-259"},"PeriodicalIF":2.0,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142741066","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Iscalimab (CFZ533) in patients with Sjögren disease: week 24 efficacy and safety results of a randomized, placebo-controlled, phase 2b dose-ranging study","authors":"Thomas Grader-Beck ,&nbsp;Benjamin A. Fisher ,&nbsp;Xavier Mariette ,&nbsp;Athena Papas ,&nbsp;Hendrika Bootsma ,&nbsp;Wan-Fai Ng ,&nbsp;P.L.A. Van Daele ,&nbsp;Stephanie Finzel ,&nbsp;Sergio Elgueta ,&nbsp;Josef Hermann ,&nbsp;Sara S. McCoy ,&nbsp;Arthur Bookman ,&nbsp;Monika Sopala ,&nbsp;Wen-Lin Luo ,&nbsp;Cornelia Scheurer ,&nbsp;Wolfgang Hueber","doi":"10.1016/j.oooo.2024.10.096","DOIUrl":"10.1016/j.oooo.2024.10.096","url":null,"abstract":"<div><h3>Objective</h3><div>Sjögren disease (SjD) is an autoimmune disease with no approved systemic treatments. Here, the week 24 results from TWINSS, a phase 2b dose-ranging trial assessing the safety and efficacy of multiple doses of iscalimab, an anti-CD40 mAb, in 2 patient populations with SjD are presented.</div></div><div><h3>Methods</h3><div>Patients fulfilling American College of Rheumatology/European League Against Rheumatism (EULAR) 2016 classification criteria and stimulated salivary flow (SF) rates of ≥0.1 mL/min, were included. In cohort 1 (C1), patients with EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI) ≥5 and EULAR Sjögren's Syndrome Patient Reported Index (ESSPRI) ≥5 were randomized (1:1:1:1) to placebo or iscalimab 150, 300, or 600 mg subcutaneously once every 2 weeks. In cohort 2 (C2), patients with ESSDAI &lt;5, ESSPRI (fatigue or dryness) ≥5, and impact of dry eye on everyday life ≥30 were randomized (1:1) to placebo or iscalimab 600 mg. Multiple comparison procedure–modeling was used to assess the dose response of ESSDAI change from baseline (C1) and a mixed model for repeated measures to estimate the placebo-adjusted mean change from baseline of ESSDAI (C1 and C2).</div></div><div><h3>Results</h3><div>In total, 173 patients were assigned to C1 and 100 to C2. In C1, ESSDAI change from baseline at week 24 showed significant improvements with iscalimab 150 and 600 mg compared with placebo (least square mean difference [Δ]: −3.0 and −2.9, respectively; <em>P</em> &lt; .005); the 300-mg dose showed a similar trend (Δ: −1.4; <em>P</em> = .16). The primary objective of a significant dose-response based on ESSDAI change from baseline at week 24 (<em>P</em> = .004) with a log-linear dose response was met. ESSPRI, FACIT-F, and SF rates showed trends of improvement with iscalimab. In C2, the primary objective of ESSPRI change from baseline showed a strong trend (Δ: −0.57; <em>P</em> = .12) toward improvement; dryness (<em>P</em> = .016) and fatigue (<em>P</em> = .067) were the response drivers. A significant increase in SF rates was observed with iscalimab. At week 24, SAE rates in C1 (placebo, iscalimab 150, 300, and 600 mg) were 2.3%, 2.3%, 7.1%, and 9.1%, respectively; in C2, the rate was 4% for both groups.</div></div><div><h3>Conclusions</h3><div>Iscalimab was well tolerated and showed improvements over placebo in 2 distinct SjD populations, and important signals for improvement in salivary flow.</div></div>","PeriodicalId":49010,"journal":{"name":"Oral Surgery Oral Medicine Oral Pathology Oral Radiology","volume":"139 2","pages":"Page e50"},"PeriodicalIF":2.0,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143173839","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Results of a phase 1, open-label, dose-escalation study of gene therapy with AAV2-hAQP1 as treatment for grade 2 and 3 radiation-induced late xerostomia and parotid gland hypofunction","authors":"Michael Brennan ,&nbsp;Michael Passineau ,&nbsp;Deborah Saunders ,&nbsp;Herve Sroussi ,&nbsp;Dyani Gaudilliere ,&nbsp;Arthur Fernandez ,&nbsp;Jun Liu ,&nbsp;Nathalie Dubois ,&nbsp;Robert Zeldin","doi":"10.1016/j.oooo.2024.10.103","DOIUrl":"10.1016/j.oooo.2024.10.103","url":null,"abstract":"<div><h3>Objective</h3><div>Grade 2/3 late xerostomia is a chronic, debilitating complication of radiotherapy for head and neck cancers. We assessed the safety and efficacy of AAV2-hAQP1 gene therapy as a treatment for this condition.</div></div><div><h3>Methods</h3><div>Twenty-four participants with grade 2/3 xerostomia at least 5 years after completing radiotherapy (2 years if HPV+) were enrolled in this multicenter, open-label, dose-escalation study. AAV2‑hAQP1 was delivered to the parotid gland(s) via cannulation of the Stensen duct. Twelve participants received AAV2-hAQP1 in 1 gland and 12 in both glands. Participants were followed for 12 months posttreatment. Safety parameters included adverse events, physical examinations, laboratory tests, and electrocardiograms. Efficacy assessments included the Xerostomia-specific Questionnaire (XQ), MD Anderson Symptom Inventory-Head and Neck Module (MDASI-HN), Global Rate of Change Questionnaire (GRCQ), and measurement of unstimulated and stimulated whole saliva flow rates (UWSFR, SWSFR).</div></div><div><h3>Results</h3><div>No treatment-related serious adverse events or dose-limiting toxicities were reported, and all participants completed the study. Statistically significant improvements were seen in the patient-reported outcome instruments by day 30 and were maintained through month 12, with greater improvement in the bilateral versus unilateral cohorts. At month 12, the mean percent change from baseline (%CFB) was −39.5% and −42.2% for the XQ Total Score and the Dry Mouth question of the MDASI-HN, respectively, and the mean GRCQ symptom score was 3.8. Overall, 16 of 24 participants reported an improvement of ≥8 points in the XQ Total Score, and 19 of 24 participants reported important improvements in xerostomia symptoms based on the GRCQ. The improvement reported across patient-reported outcome instruments, measuring different aspects of xerostomia symptoms, provides compelling evidence of treatment effectiveness. The mean %CFB in UWSFR at month 12 was 112.5%, and a trend toward improved SWSFR was observed.</div></div><div><h3>Conclusion</h3><div>Treatment with AAV2-hAQP1 was safe and well-tolerated at all doses and resulted in meaningful improvements in xerostomia symptoms and unstimulated whole saliva flow rate.</div></div>","PeriodicalId":49010,"journal":{"name":"Oral Surgery Oral Medicine Oral Pathology Oral Radiology","volume":"139 2","pages":"Pages e53-e54"},"PeriodicalIF":2.0,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143174463","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The intended and incidental","authors":"Abdulrahman Nakshabandi ,&nbsp;Joud Omari ,&nbsp;Petros Yoon ,&nbsp;Hervè Sroussi","doi":"10.1016/j.oooo.2024.10.112","DOIUrl":"10.1016/j.oooo.2024.10.112","url":null,"abstract":"<div><h3>Background</h3><div>Melanoma is a malignancy originating from melanocytes, with the potential to affect not only the skin but also any melanocyte-containing tissue, including mucosal surfaces. Mucosal melanoma (MM), although less common than its cutaneous counterpart, is characterized by a more aggressive course and poorer prognosis. In the head and neck region, MM primarily involves the nasal and sinonasal cavities, with the oral cavity being less frequently affected, particularly at the hard palatal mucosa and maxillary gingiva. Distinct from cutaneous melanoma, which has a well-established link to ultraviolet exposure, MM lacks definitive risk factors. This gap in understanding poses a significant challenge in early detection and prevention strategies. The prognosis remains dire, as evidenced by a 5-year overall survival rate ranging from 0 to 45%, largely due to late-stage diagnosis.</div></div><div><h3>Case Summary</h3><div>A 65-year-old female patient with a history of hypertension, eczema, and hyperlipidemia was notified by her general dentist during routine dental prophylaxis of a pigmented macule on the left hard palatal mucosa. Routine surveillance was recommended. Three months later, she noted an asymptomatic blister-like swelling in the same area as what she believed to be the unchanged macule. Two months later, the patient presented to the oral medicine clinic. Intra-oral examination revealed a 2.0- × 1.3- × 0.4-cm ulcerated brown sessile mass, concerning for neoplasia. An incisional biopsy revealed mucosal melanoma. Comprehensive imaging work-up, including positron emission tomography and computed tomography, revealed an incidental fluorodeoxyglucose-avid lung nodule. Biopsy of the nodule revealed primary lung adenocarcinoma. Treatment will include left hemi-maxillectomy for the MM, followed by evaluation by thoracic surgery and radiation oncology for treatment of the lung adenocarcinoma.</div></div><div><h3>Conclusions</h3><div>MM is a rare, aggressive malignancy with a poor prognosis that can affect the oral cavity. Oral health providers should routinely screen for suspicious pigmented lesions to facilitate early diagnosis and treatment. Additionally, it has been reported that patients with MM are more likely to have a second primary malignancy compared with those with other types of melanoma. Herein, we present such a case of primary oral MM and primary lung adenocarcinoma that was diagnosed incidentally during the MM workup process.</div></div>","PeriodicalId":49010,"journal":{"name":"Oral Surgery Oral Medicine Oral Pathology Oral Radiology","volume":"139 2","pages":"Page e57"},"PeriodicalIF":2.0,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143174474","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sarcoidosis affecting the maxilla: report of 2 cases","authors":"Joud Y Omari ,&nbsp;Eric Saiz ,&nbsp;Daniel Hawkins ,&nbsp;Sook-Bin Woo","doi":"10.1016/j.oooo.2024.10.111","DOIUrl":"10.1016/j.oooo.2024.10.111","url":null,"abstract":"<div><div>Sarcoidosis is a granulomatous disease that is likely a hypersensitivity reaction to an environmental agent, characterized by the presence of noncaseating granulomas typically affecting the hilar lymph nodes and the lungs. The disease affects adults in their third to fifth decades and extramediastinal involvement affects mainly the lymph nodes, liver, skin, and eyes. Within the oral cavity, sarcoidosis affects the minor salivary glands in 25% to 50% of patients. Osseous involvement has been documented in 3% to 13% of patients but only 26 cases have been reported in the jawbones.</div><div>Here we present 2 new cases of sarcoidosis affecting the jaw bones. The first case was that of a 65-year-old female patient with a known history of sarcoidosis with respiratory symptoms managed with budesonide inhaler who presented with an expansile radiolucent lesion of the anterior maxilla in the area of the right maxillary canine and incisors. The second case is of a 55-year-old female patient with stable pulmonary sarcoidosis not currently undergoing therapy who presented with a radiolucency of the right maxilla with the right maxillary canine “floating in space.” The differential diagnoses included odontogenic cysts and tumors, Langerhans cell histiocytosis, and central giant cell granuloma.</div><div>Biopsies from both patients revealed non-necrotizing granulomatous inflammation consistent with the patients’ known history of sarcoidosis. Histochemical studies to rule out an infectious cause for the granulomas were negative. Of the 26 previously reported cases of sarcoidosis involving the jaw bones, the mean age at diagnosis was 37.4 years (range 16-59 years) and there was a female predilection (1.9:1) Involvement of jaw bones was observed primarily in tooth-bearing areas with two cases affecting the mandibular condyles. The mandible and maxilla were equally affected in 38.5% of cases and all presented as poorly defined radiolucencies. In four cases, there was generalized involvement of both the mandible and the maxilla. In 11 cases (42.3%), oral involvement preceded identification of systemic disease. Management of patients ranged from surgical to nonsurgical intervention including the use of steroid treatment. Patients who received surgical treatment exhibited improvement of the jaw lesions, often exhibiting osseous regeneration on follow-up visits.</div></div>","PeriodicalId":49010,"journal":{"name":"Oral Surgery Oral Medicine Oral Pathology Oral Radiology","volume":"139 2","pages":"Page e57"},"PeriodicalIF":2.0,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143174786","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correlation of the expression of the interleukin-1 signaling pathway with prognostic factors in oral squamous cell carcinoma: an immunohistochemical study","authors":"Felipe Martins Silveira ,&nbsp;Sven Eric Niklander ,&nbsp;Wilfredo Alejandro Gonzalez Arriagada ,&nbsp;René Martínez-Flores ,&nbsp;Ronell Eduardo Bologna-Molina","doi":"10.1016/j.oooo.2024.10.106","DOIUrl":"10.1016/j.oooo.2024.10.106","url":null,"abstract":"<div><h3>Objective</h3><div>Interleukin (IL)-1 comprises a family of inflammation-regulating cytokines that govern various innate immune processes. This study aims to evaluate the immunohistochemical expression of IL-1 family members in oral squamous cell carcinoma (OSCC) and elucidate the association of their expression with clinicopathological features.</div></div><div><h3>Methods</h3><div>Immunohistochemical expressions of IL-1α, IL-1β, IL-1RA, and IL-1R1 were assessed in the parenchyma (invasion front) of 44 OSCC resections. Immunoreactivity was evaluated in association with histologic grade, perineural invasion, recurrence, and clinical staging of OSCC cases. The χ² test was employed to correlate expression levels of IL-1 family members with clinicopathologic variables, and Cox regression was used to identify independent risk factors related to poor 5-year survival.</div></div><div><h3>Results</h3><div>Tumor islands at the invasion front of all evaluated OSCC cases were positive, showing varying degrees of immunoreactivity for IL-1α, IL-1β, IL-1RA, and IL-1R1, with a greater proportion of cases exhibiting high IL-1RA expression (62.5%). Low IL-1α immunoreactivity demonstrated a statistically significant association with increased recurrence (<em>P</em> = .007) and less-differentiated tumors (<em>P</em> = .036). No significant association of other IL-1 family members with any evaluated prognostic factors was observed.</div></div><div><h3>Conclusions</h3><div>The results suggest that reduced tissue expression of IL-1α is associated with increased recurrence and less-differentiated OSCC cases. The role of pro-inflammatory factors in the IL-1 signaling pathway appears to be more crucial in etiopathogenesis than in the prognostic factors of OSCC.</div></div>","PeriodicalId":49010,"journal":{"name":"Oral Surgery Oral Medicine Oral Pathology Oral Radiology","volume":"139 2","pages":"Page e55"},"PeriodicalIF":2.0,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143173349","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}